KELIX bio, owned by Mubadala Investment Company, has announced that it has completed the acquisition of DiabTec LLC, a subsidiary of Julphar.
Publish dateThursday 16 January 2025 - 22:46
According to Amac News: Based on the Mubadala announcement, this purchase strengthens the portfolio of this company in the field of biologicals and strengthens its role in biological production in the MENA region.
The DiabTec facility includes 20,000 liter capacity pharmaceutical reactors and a separate filling and packaging facility for pharmaceutical products.
This state-of-the-art facility was built in accordance with EU and US FDA standards and is currently the only facility of its kind in the Persian Gulf.
Saqr bin Hamid Al Qasimi, Chairman of Julphar's Board of Directors, said: "The sale of this facility is part of Julphar's strategy to divest non-nuclear assets. Julphar supports the exchange to strengthen the pharmaceutical sector in the UAE and build wider API production capabilities in the country."
The DiabTec facility includes 20,000 liter capacity pharmaceutical reactors and a separate filling and packaging facility for pharmaceutical products.
This state-of-the-art facility was built in accordance with EU and US FDA standards and is currently the only facility of its kind in the Persian Gulf.
Saqr bin Hamid Al Qasimi, Chairman of Julphar's Board of Directors, said: "The sale of this facility is part of Julphar's strategy to divest non-nuclear assets. Julphar supports the exchange to strengthen the pharmaceutical sector in the UAE and build wider API production capabilities in the country."
amacnews.com/vdcg.z9xrak93nj54a.html
Source : news agency wam
Most viewed
